VGF immunoreactivity reduction in the ALS animal model was observed using one VGF commercial antibody, referred to as the antibody against the VGF full length; however, the molecular weight (MW) forms it recognized were not investigated [70]. Here, VGF is linked to amyotrophic lateral sclerosis.